CTT Pharmaceutical Holdings, Inc.
CTT Pharmaceutical Holdings, Inc.
Your view on CTTH
Overview
What the company does, where it operates, and who runs it.
About CTT Pharmaceutical Holdings, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Ryan Khouri
- Headquarters
- 429 Kent Street unit 112, Ottawa, ON, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Ryan Khouri
- Headquarters
- 429 Kent Street unit 112, Ottawa, ON, CA
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems.
The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion.
Its principal asset is a patented orally administered wafer, an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015. The company is based in Ottawa, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for CTT Pharmaceutical Holdings, Inc., and the rating behind it. CTTH last traded at $0.09; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for CTT Pharmaceutical Holdings, Inc.. Starting points for CTT Pharmaceutical Holdings, Inc.: beta 0.40 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for CTT Pharmaceutical Holdings, Inc.. CTT Pharmaceutical Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for CTT Pharmaceutical Holdings, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for CTT Pharmaceutical Holdings, Inc.. CTT Pharmaceutical Holdings, Inc. has reported as a listed company since 1997. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
CTT Pharmaceutical Holdings, Inc. valued side by side against its closest peers. CTT Pharmaceutical Holdings, Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold CTT Pharmaceutical Holdings, Inc., and how their positions are changing. At a $1.9M market value, institutional positions materially move CTT Pharmaceutical Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by CTT Pharmaceutical Holdings, Inc. executives and directors. Shares of CTT Pharmaceutical Holdings, Inc. have traded between $0.02 and $0.13 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming CTT Pharmaceutical Holdings, Inc.. CTT Pharmaceutical Holdings, Inc. is a $1.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming CTT Pharmaceutical Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for CTT Pharmaceutical Holdings, Inc.. Coverage tracks CTT Pharmaceutical Holdings, Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.